In Week of Mar 28, 2026, Lincoln Pharmaceuticals Ltd (Pharma - Formulators) is outperforming Nifty 500 with +33.2% relative strength. Fundamentals: Average. On a 7-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: Management reaffirmed target with possible 5-6 month extension from original timeline
Impact: +₹600 Cr revenue
“Overall our growth and the target for thousand CR is still there and we will achieve it anyhow”
What: Guidance on EBITDA margins improving from current 13.19% through better product mix
“to be secure enough I can say that between 15 to 18% we will”
What: Three products submitted for approval with potential for additional submissions
Impact: +₹45 Cr revenue
“already submitted three products and once uh these uh approvals are clear we can again push up to more products”
Earnings deceleration risks from management commentary
Trigger: Decline in other income
Impact: -300 bps margin impact
Management view: Not directly addressed in con-call
Monitor: Other income as % of PBT
Trigger: Continued quarterly revenue fluctuations
Impact: -100 bps margin impact
Management view: Not directly addressed in con-call
Monitor: Quarterly revenue growth consistency
Key quotes from recent conference calls
“Overall our growth and the target for thousand CR is still there and we will achieve it anyhow — Management”
“a better product mix and operating discipline supported the current quarter's profit growth — Munjal Patel, Director”
“we are doing all the activities possible into various regions and various areas also in the therapeutic index wherever we are possible we can do that — Management”
“to be secure enough I can say that between 15 to 18% we will — Management”
Forward-looking targets from management for 3 years
Revenue Growth Target
60%
Implied PAT Growth
25%
OPM Guidance
15%
Key Milestones
• ₹1,000 cr revenue by FY28/29
• 15-18% EBITDA margins
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +13% | +10% | Stable |
| PAT (Net Profit) | +38% | +6% | Inflection Up |
| OPM | 14.0% | -200 bps | Stable |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Lincoln Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
Lincoln Pharmaceuticals Ltd's profit is growing with an turning around (inflection up) trend.
Lincoln Pharmaceuticals Ltd's revenue growth trend is stable.
Lincoln Pharmaceuticals Ltd's operating margin is stable.
Lincoln Pharmaceuticals Ltd's long-term compounding rates
Lincoln Pharmaceuticals Ltd's earnings growth is turning around (inflection up) with mixed signals on a sequential basis.
Lincoln Pharmaceuticals Ltd's trailing twelve month (TTM) performance
Lincoln Pharmaceuticals Ltd appears significantly overvalued based on our fair value analysis.
Lincoln Pharmaceuticals Ltd's current PE ratio is 13.3x.
Lincoln Pharmaceuticals Ltd's current PE is 13.3x.
Lincoln Pharmaceuticals Ltd's price-to-book ratio is 1.6x.
Lincoln Pharmaceuticals Ltd is rated Average with a fundamental score of 54.79/100. This score is calculated from objective financial metrics
Lincoln Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
Lincoln Pharmaceuticals Ltd's return ratios over recent years
Lincoln Pharmaceuticals Ltd's operating cash flow is positive (FY2025).
Lincoln Pharmaceuticals Ltd's current dividend yield is 0.31%.
Lincoln Pharmaceuticals Ltd's shareholding pattern (Dec 2025)
Lincoln Pharmaceuticals Ltd's promoter holding has remained stable recently.
Lincoln Pharmaceuticals Ltd has been outperforming Nifty 500 for 7 consecutive weeks, indicating building momentum.
Lincoln Pharmaceuticals Ltd is an established outperformer with 7 weeks of consecutive Nifty 500 outperformance.
Lincoln Pharmaceuticals Ltd has 3 key growth catalysts identified from recent earnings analysis
Lincoln Pharmaceuticals Ltd has 2 key risks worth monitoring
In Q3 FY26, Lincoln Pharmaceuticals Ltd's management highlighted
Lincoln Pharmaceuticals Ltd's management has provided the following forward guidance for 3 years
Based on quantitative research signals, here is why Lincoln Pharmaceuticals Ltd may be worth studying
Lincoln Pharmaceuticals Ltd investment thesis summary:
Lincoln Pharmaceuticals Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
